A new study led by researchers at Emory University’s Rollins School of Public Health, published Monday by JAMA Network Open, estimates that nearly 20% of U.S. residents who use pre-exposure prophylaxis (PrEP) for HIV prevention—or more than 110,000 of the approximately 580,000 PrEP users nationwide in 2024—received their medication via telemedicine.
Continue Reading this article here
